Table 1:
Baseline characteristics of the study population
| Omalizumab | Mepolizumab | +Dupilumab | |
|---|---|---|---|
| Overall sample size, n | 68 | 65 | 68 |
| Age (mean, sd) | 47.7 (16.2) | 54.5 (13.6) | 51.7 (13.9) |
| Female sex, n (%) | 54 (79.4%) | 43 (66.2%) | 42 (61.8%) |
| Body mass index (mean, sd) | 30.1 (7.8) | 29.2 (7.5) | 28.3 (6.6) |
| Race: | |||
| White, n (%) | 52 (76.5%) | 49 (75.4%) | 54 (79.4%) |
| Black, n (%) | 3 (4.4%) | 9 (13.8%) | 4 (5.9%) |
| Asian, n (%) | 2 (2.9%) | 0 (0.0%) | 4 (5.9%) |
| Ethnicity: | |||
| Hispanic, n (%) | 2 (2.9%) | 2 (3.1%) | 1 (1.5%) |
| Residence in inner city, n% | 11 (16.2%) | 8 (12.3%) | 13 (19.1%) |
| *Private insurance | 48 (70.6%) | 47 (72.3%) | 55 (80.9%) |
| Concomitant medications | |||
| ICS/LABA, n (%) | 35 (51.5%) | 39 (60.0%) | 42 (61.8%) |
| LAMA, n (%) | 17 (25.0%) | 24 (36.9%) | 14 (20.6%) |
| OCS, n (%) | 4 (5.9%) | 4 (6.2%) | 2 (2.9%) |
| Baseline eosinophil count (cells/mcL), median (IQR) | 305 (190 – 472) | 630 (400 – 1010) | 410 (278 – 642) |
| Baseline Immunoglobulin E (IU/ml), median (IQR) | 144 (80 – 276) | 120 (65 – 295) | 166 (74 – 285) |
| Pre-index annualized exacerbation rate (mean, sd) | 0.8 (1.6) | 1.1 (1.4) | 0.8 (1.2) |
| Pre-bronchodilator FEV1, liters (median, IQR) | 2.1 (1.7–2.7) | 2.2 (1.7–2.8) | 2.0 (1.5–2.6) |
| Pre-bronchodilator FEV1 percent predicted, % (median, IQR) | 83 (69 – 92) | 72 (62– 83) | 81 (69 – 93) |
| Charlson Comorbidity Index, mean (sd) | 1.2 (0.8) | 1.3 (0.7) | 1.1 (1.1) |
| Smoking status | |||
| Current, n (%) | 2 (2.9%) | 3 (4.6%) | 5 (7.4%) |
| Former, n (%) | 13 (19.1%) | 9 (13.8%) | 15 (22.1%) |
| Never, n (%) | 44 (64.7%) | 41 (63.1%) | 37 (54.4%) |
| Unknown, n (%) | 9 (13.2%) | 12 (18.5%) | 11 (16.2%) |
| Allergic rhinitis, n (%) | #63 (92.6%) | 48 (73.8%) | 55 (80.9%) |
| Season of initiation in Winter | |||
| Winter, n (%) | 9 (13.2%) | 13 (20.0%) | 26 (38.2%) |
Abbreviations: IQR, interquartile range; ICS/LABA, inhaled corticosteroids/long-acting beta-agonists; LAMA, long-acting muscarinic antagonist; OCS, oral corticosteroids.
+
66 (97%) of the 68% patients on dupilumab were using the 300 mg every 2-week dose.
*
No patient within this cohort was uninsured
#
The five patients on omalizumab “without allergic rhinitis” with missing perennial allergic rhinitis as shown in Table 1 all had IgE within the accepted level for omalizumab dosing and noted diagnosis of perennial rhinitis based on history in chart. However, we did not see the objective evidence of testing to perennial allergens.